Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.38 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: adenosine, pentoxifylline, las101057 +8 | 1.00 |
| trials ClinicalTrials.gov | 21 Parkinson's trials, 3 stopped | 0.89 |
| literature PubMed | 3 Parkinson's papers of 250 | 0.82 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 0673
Sealed predictions
- ADORA2B in dopamine neurons, braak+0.18 (p 0.648) → -0.23 (p 0.549)receipt 0679
Swarm cases
receipt 0679: ADORA2B in dopamine neurons, braak
- power
- full sample -0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.04 (p 0.861, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.11, sign flips 9; without severely affected donors -0.00 (p 0.997, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADORA2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts